CFM
KRYS icon

Cornerstone Financial Management’s Krystal Biotech KRYS Stock Holding History

Cornerstone Financial Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.2K Hold
14
– – ﹤0.01% 610
2026
Q1 		$3.62K Hold
14
– – ﹤0.01% 569
2025
Q4 		$3.45K Buy
+14
New +$2.95K ﹤0.01% 525

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cornerstone Financial Management's KRYS Position: Q2 2026 in Review

Cornerstone Financial Management held its Krystal Biotech (KRYS) position steady in Q2 2026 at 14 shares worth $5.2K. The position accounts for ﹤0.01% of the portfolio, ranked #610.

Cornerstone Financial Management first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cornerstone Financial Management held 14 shares of Krystal Biotech worth $5.2K as of Q2 2026.
  • Cornerstone Financial Management left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #610 holding.
  • Cornerstone Financial Management first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.